Xbrane: We Are Not Convinced On European IQVIA Ranibizumab Data
Positive Cash Flow Ambition Pushed Back Amid Challenges, Continued Development Costs
Executive Summary
Swedish biosimilars player Xbrane spoke candidly about its recent launch of the company’s first product, the Stada-partnered Ximluci biosimilar to Lucentis in Europe, as it updated on the company’s ongoing hunt for a new US commercialization partner.
You may also be interested in...
Stada, Biogen Bring Greater Ranibizumab Competition To EU And UK
April brings news of further biosimilar competition to Lucentis in major European markets.
Xbrane Eyes Positive Cash Flow In 2024 – But Out-Licensing Oncology Key
Xbrane has spelled out ambitious cash goals beginning next year, which hinge largely on it finding a partner for its pre-clinical oncology candidates, as it continues to shoulder heavy development and regulatory costs for its suite of biosimilars.
Alvotech’s Japanese Ustekinumab Nod Is ‘First For Global Markets’
Following the formation of their partnership nearly five years ago, Alvotech and Fuji have together welcomed approval in Japan for Alvotech’s biosimilar to Stelara (ustekinumab).